Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

NCT03010176 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Lymphoma

Interventions

DRUG: Ulevostinag
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC